Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.57 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.43 |
| ▸ | TAB1 | Q15750 | 2/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 3/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6925170 | 0.87 | BTK (0.45) | BTKMAP3K7TAB1METHRH3 | |
| SCHEMBL10260771 | 0.84 | BTK (0.60) | BTKMAP3K7TAB1METATR | |
| SCHEMBL6925932 | 0.71 | BTK (0.54) | BTKMETALK | |
| SCHEMBL6927094 | 0.71 | BTK (0.56) | BTKMETALK | |
| SCHEMBL6924755 | 0.70 | EPHB4 (0.35) | BTKMET | |
| SCHEMBL10198705 | 0.70 | KDR (0.57) | BTKMETALK | |
| SCHEMBL6927400 | 0.70 | EIF2AK3 (0.41) | BTKMETHTR2C | |
| SCHEMBL21105139 | 0.68 | HTR2C (0.42) | MAP3K7TAB1HRH3HTR2C | |
| SCHEMBL6924514 | 0.68 | EPHB4 (0.58) | BTK | |
| SCHEMBL16154952 | 0.64 | HTR2C (0.56) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018038-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | BTK 2336/4885MAP3K7 209/4885TAB1 548/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | BTK 2336/4885MAP3K7 209/4885TAB1 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.